CD274 and neoplasm: Recently more and more predictive biomarkers have been used in immunotherapy research, such as tumor mutation burden (TMB), programmed cell death ligand 1 (PD-L1), and mismatch repair defect (dMMR)/microsatellites Instability (MSI) 2,3.